REFERENCES
F. Delie and W. Rubas. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: Advantages and limitations of the Caco-2 model. Crit. Rev. Ther. Drug Carrier Syst. 14:221-286 (1997).
E. Liang, K. Chessic, and M. Yazdanian. Evaluation of an accelerated Caco-2 cell permeability model. J. Pharm. Sci. 89:336-345 (2000).
J. H. Hochman, M. Chiba, J. Nishime, M. Yamazaki, and J. H. Lin. Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J. Pharmacol. Exp. Ther. 292:310-318 (2000).
P. Artursson and R. T. Borchardt. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm. Res. 14:1655-1658 (1997).
V. Pade and S. Stavchansky. Link between drug absorption solubility and permeability measurements in Caco-2 cells. J. Pharm. Sci. 87:1604-1607 (1998).
S. D. Flanagan and L. Z. Benet. Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2monolayers and excised rat jejunum. Pharm. Res. 16:221-224 (1999).
L. Z. Benet and C. Y. Wu: Method for increasing bioavailability of oral pharmaceutical compositions. United States Patent #6028054, February 22, 2000.
M. A. Gibbs, M. T. Baillie, D. D. Shen, K. L. Kunze, and K. E. Thummel. Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells. Pharm. Res. 17:299-305 (2000).
W. L. Chiou. We may not measure the correct intestinal wall permeability coefficient of drugs: Alternative absorptive clearance concept. J. Pharmacokinet. Biopharm. 23:323-331 (1995).
W. L. Chiou. Commentary: New perspectives on the theory of permeability and resistance in the study of drug transport and absorption. J. Pharmacokinet. Biopharm. 24:433-42 (1996).
V. D. Makhey, A. Guo, D. A. Norris, P. Hu, J. Yan, and P. J. Sinko. Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm. Res. 15:1160-1167 (1998).
L. Z. Benet, S. Øie, and J. B. Schwarts. Design and Optimization of dosage regimens; Pharmacokinetic data. In A. Goodman Gilman, J. G. Hardman, L. E. Limbard, P. B. Molinoff, and R. W. Ruddon (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition, McGraw Hill, NY, 1996 pp. 1707-1792.
M. G. Lee and W. L. Chiou. Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism. J. Pharmacokinet. Biopharm. 11:623-640 (1983).
P. Manitpisitkul and W. L. Chiou. Intravenous verapamil kinetics in rats: marked arteriovenous concentration difference and comparison with humans. Biopharm. Drug. Dispos. 14:555-566 (1993).
G. A. Sawada, N. F. H. Ho, L. R. Williams, C. L. Barsuhn, and T. J. Raub. Transcellular permeability of chlorpromazine demonstrating the roles of protein binding and membrane partitioning. Pharm. Res. 11:665-673 (1994).
R. K. Verbeeck, J. A. Cardinal, A. G. Hill, and K. K. Midha. Binding of phenothiazine neuroleptics to plasma proteins. Biochem. Pharmacol. 32:2565-2570 (1983).
Y. Imamura and H. Ichibagase. Effect of simultaneous administration of drugs on absorption and excretion. VIII. Effect of plasma-protein binding displacement on the intestinal absorption of sulfonamides in rabbits. Chem. Pharm. Bull. 25:3400-3405 (1977).
W. L. Chiou. Determination of drug permeability in a flat or distended stirred intestine. Prediction of fraction dose absorbed in humans after oral administration. Int. J. Clin. Pharmacol. Ther. 32:474-82 (1994).
R. A. Walgren and T. Walle. The influence of plasma binding on absorption/exsorption in the Caco-2 model of human intestinal absorption. J. Pharm. Pharmacol. 51:1037-1040 (1999).
W. L. Chiou and F. H. Hsu. Correlation of unbound plasma clearances of fifteen extensively metabolized drugs between humans and rats. Pharm. Res. 5:668-672 (1988).
W. L. Chiou, S. M. Chung, and T. C. Wu. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharm. Res. 17:205-208 (2000).
S. M. Chung and W. L. Chiou. Potential overestimation of the role of gastrointestinal metabolism and p-glycoprotein mediated efflux in contributing to low bioavailability of drugs in humans. PharmSci Suppl. 1:Presentation 4272 (1999).
Physicians' Desk Reference, 54th edition, Medical Economics Company, Montvale, NJ, 2000.
H. J. Kuhnel, K. Gunther, G. Stein, and A. Hoffmann-Traeger. Pharmacokinetics and pharmacodynamics of high dose furosemide in patients with chronic renal failure or nephrotic syndrome. Int. J. Clin. Pharmacol. Ther. Toxicol. 25:616-621 (1987).
R. Sandstrom, T. W. Knutson, L. Knutson, B. Jansson, and H. Lennernäs. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br. J. Clin. Pharmacol. 48:180-189 (1999).
W. L. Chiou, S. M. Chung, T. C. Wu, and C. Ma. Commentary: A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. (March, 2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chung, S.M., Park, E.J., Swanson, S.M. et al. Profound Effect of Plasma Protein Binding on the Polarized Transport of Furosemide and Verapamil in the Caco-2 Model. Pharm Res 18, 544–547 (2001). https://doi.org/10.1023/A:1011022931368
Issue Date:
DOI: https://doi.org/10.1023/A:1011022931368